Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) traded down 5.2% on Monday . The stock traded as low as $1.90 and last traded at $1.99. 565,302 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 1,033,985 shares. The stock had previously closed at $2.10.

CAPR has been the topic of a number of research analyst reports. ValuEngine raised shares of Capricor Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. HC Wainwright raised their price objective on shares of Capricor Therapeutics from $2.15 to $6.50 and gave the stock a “buy” rating in a report on Friday, September 15th. Finally, Zacks Investment Research raised shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a report on Wednesday, August 16th.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.07. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $1.00 million. During the same period in the previous year, the business posted ($0.29) EPS. The firm’s revenue for the quarter was down 58.7% compared to the same quarter last year. sell-side analysts anticipate that Capricor Therapeutics, Inc. will post -0.7 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN acquired a new stake in Capricor Therapeutics during the third quarter worth approximately $107,000. Virtu KCG Holdings LLC raised its holdings in Capricor Therapeutics by 571.9% during the second quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 152,614 shares in the last quarter. LLBH Private Wealth Management LLC raised its holdings in Capricor Therapeutics by 27.7% during the second quarter. LLBH Private Wealth Management LLC now owns 184,591 shares of the biotechnology company’s stock worth $153,000 after purchasing an additional 40,000 shares in the last quarter. Jane Street Group LLC acquired a new stake in Capricor Therapeutics during the third quarter worth approximately $190,000. Finally, Belpointe Asset Management LLC acquired a new stake in Capricor Therapeutics during the third quarter worth approximately $249,000. 3.09% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/28/capricor-therapeutics-inc-capr-stock-price-down-5-2.html.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Receive News & Stock Ratings for Capricor Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc. and related stocks with our FREE daily email newsletter.